The US Patent and Trademark Office (USPTO) has issued a notice of allowance for Sangamo BioSciences’ patent application entitled ‘Novel DNA-binding Proteins and Uses Thereof.’
Claims cover the critical components of TALE Technology, including core architectural aspects of engineered Transcription Activator-Like Effectors (TALEs).
When integrated with Sangamo's proprietary engineered FokI nucleases, or DNA cutting domains, the technology can be used to efficiently and precisely edit gene sequences.
Sangamo president and CEO Edward Lanphier said the company is developing proprietary zinc finger DNA-binding (ZFP) technology for therapeutic applications in HIV/AIDS and the treatment of monogenic diseases.
"We are very pleased that the U.S. Patent Office has acknowledged these new claims which expand and reinforce our dominance of this field from both a scientific and intellectual property perspective," Lanphier added.
